{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:41:53Z","timestamp":1787164913203,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T00:00:00Z","timestamp":1554508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-019-1281-y","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T04:03:22Z","timestamp":1554523402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus"],"prefix":"10.1186","volume":"19","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,6]]},"reference":[{"issue":"9","key":"1281_CR1","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/epi.13837","volume":"58","author":"A Strzelczyk","year":"2017","unstructured":"Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia. 2017;58(9):1533\u201341.","journal-title":"Epilepsia"},{"issue":"6","key":"1281_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s11910-014-0452-x","volume":"14","author":"S Hocker","year":"2014","unstructured":"Hocker S, Tatum WO, LaRoche S, Freeman WD. Refractory and super-refractory status epilepticus--an update. Curr Neurol Neurosci Rep. 2014;14(6):452.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"1281_CR3","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus--report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515\u201323.","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"1281_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1528-1167.2011.03238.x","volume":"52","author":"S Shorvon","year":"2011","unstructured":"Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia. 2011;52(Suppl 8):53\u20136.","journal-title":"Epilepsia"},{"issue":"1","key":"1281_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","volume":"17","author":"GM Brophy","year":"2012","unstructured":"Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3\u201323.","journal-title":"Neurocrit Care"},{"issue":"10","key":"1281_CR6","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00415-003-0180-7","volume":"250","author":"JM Niermeijer","year":"2003","unstructured":"Niermeijer JM, Uiterwaal CS, Van Donselaar CA. Propofol in status epilepticus: little evidence, many dangers? J Neurol. 2003;250(10):1237\u201340.","journal-title":"J Neurol"},{"issue":"12","key":"1281_CR7","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1097\/CCM.0b013e3181b08ac7","volume":"37","author":"VN Iyer","year":"2009","unstructured":"Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37(12):3024\u201330.","journal-title":"Crit Care Med"},{"issue":"9","key":"1281_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1212\/WNL.0000000000000723","volume":"83","author":"SE Hocker","year":"2014","unstructured":"Hocker SE, Shorvon S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;83(9):866.","journal-title":"Neurology"},{"issue":"10","key":"1281_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u201334.","journal-title":"J Clin Epidemiol"},{"key":"1281_CR10","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"5","key":"1281_CR11","first-page":"149","volume":"5","author":"W Zengming","year":"2011","unstructured":"Zengming W, Shengming W, Qin F, Yaohui L. Effect of propofol and thiopental on the treatment of refractory epilepsy. Chinese Modern Drug Application. 2011;5(5):149\u201350.","journal-title":"Chinese Modern Drug Application"},{"issue":"2","key":"1281_CR12","first-page":"55","volume":"2","author":"F Xiuquan","year":"2005","unstructured":"Xiuquan F, Hongtao W. Efficacy of propofol and thiopental in the treatment of refractory status epilepticus in 18 patients. Pract Hospital Clin J. 2005;2(2):55\u20136.","journal-title":"Pract Hospital Clin J"},{"issue":"72","key":"1281_CR13","first-page":"118","volume":"1","author":"C Xiang","year":"2016","unstructured":"Xiang C. Study on clinical treatment effect of refractory status epilepticus. Abstract Information World\u2019s Newest Med. 2016;1(72):118\u20139.","journal-title":"Abstract Information World\u2019s Newest Med"},{"issue":"4","key":"1281_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1212\/01.wnl.0000173066.89001.f9","volume":"65","author":"JP Gestel van","year":"2005","unstructured":"van Gestel JP, Blusse van Oud-Alblas HJ, Malingre M, Ververs FF, Braun KP, van Nieuwenhuizen O. Propofol and thiopental for refractory status epilepticus in children. Neurology. 2005;65(4):591\u20132.","journal-title":"Neurology"},{"issue":"1","key":"1281_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12028-010-9445-z","volume":"14","author":"AO Rossetti","year":"2011","unstructured":"Rossetti AO, Milligan TA, Vulliemoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14(1):4\u201310.","journal-title":"Neurocrit Care"},{"issue":"7","key":"1281_CR16","first-page":"64","volume":"23","author":"C Linzhi","year":"2017","unstructured":"Linzhi C. Effect of propofol and thiopental on the treatment of refractory epilepsy in 56 cases. Psychologist. 2017;23(7):64\u20135.","journal-title":"Psychologist"},{"issue":"7","key":"1281_CR17","first-page":"61","volume":"10","author":"Z Chunfen","year":"2017","unstructured":"Chunfen Z, Qin Z. The clinical efficacy of propofol in the treatment of refractory epilepsy. Chin J Clin Rational Drug Use. 2017;10(7):61\u20132.","journal-title":"Chin J Clin Rational Drug Use"},{"key":"1281_CR18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fneur.2017.00636","volume":"8","author":"UK Misra","year":"2017","unstructured":"Misra UK, Kalita J, Dubey D. A study of super refractory status epilepticus from India. Front Neurol. 2017;8:636.","journal-title":"Front Neurol"},{"issue":"3","key":"1281_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1046\/j.1528-1157.2001.27500.x","volume":"42","author":"A Prasad","year":"2001","unstructured":"Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42(3):380\u20136.","journal-title":"Epilepsia"},{"key":"1281_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1744-8069-1-2","volume":"1","author":"SW Ying","year":"2005","unstructured":"Ying SW, Goldstein PA. Propofol suppresses synaptic responsiveness of somatosensory relay neurons to excitatory input by potentiating GABA(a) receptor chloride channels. Mol Pain. 2005;1:2.","journal-title":"Mol Pain"},{"key":"1281_CR21","doi-asserted-by":"crossref","unstructured":"Prabhakar H, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev. 2015;25;(6):CD009202.","DOI":"10.1002\/14651858.CD009202.pub3"},{"issue":"20","key":"1281_CR22","first-page":"1031","volume":"30","author":"X Pourrat","year":"2001","unstructured":"Pourrat X, Serekian JM, Antier D, Grassin J. Generalized tonic-clonic status epilepticus: therapeutic strategy. Presse Med. 2001;30(20):1031\u20136.","journal-title":"Presse Med"},{"key":"1281_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.seizure.2017.02.015","volume":"47","author":"G Zaccara","year":"2017","unstructured":"Zaccara G, Giannasi G, Oggioni R, Rosati E, Tramacere L, Palumbo P. Challenges in the treatment of convulsive status epilepticus. Seizure. 2017;47:17\u201324.","journal-title":"Seizure"},{"issue":"29","key":"1281_CR24","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.2174\/1381612043382846","volume":"10","author":"PE Marik","year":"2004","unstructured":"Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des. 2004;10(29):3639\u201349.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"1281_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1046\/j.1528-1157.2002.28501.x","volume":"43","author":"J Claassen","year":"2002","unstructured":"Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43(2):146\u201353.","journal-title":"Epilepsia"},{"issue":"7","key":"1281_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1179\/016164107X240044","volume":"29","author":"I Parviainen","year":"2007","unstructured":"Parviainen I, Kalviainen R, Ruokonen E. Propofol and barbiturates for the anesthesia of refractory convulsive status epilepticus: pros and cons. Neurol Res. 2007;29(7):667\u201371.","journal-title":"Neurol Res"},{"issue":"1","key":"1281_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/ene.12531","volume":"22","author":"R Sutter","year":"2015","unstructured":"Sutter R, Kaplan PW, Marsch S, Hammel EM, Ruegg S, Ziai WC. Early predictors of refractory status epilepticus: an international two-center study. Eur J Neurol. 2015;22(1):79\u201385.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1281_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1055\/s-0034-1384752","volume":"35","author":"GL Bassi","year":"2014","unstructured":"Bassi GL, Ferrer M, Marti JD, Comaru T, Torres A. Ventilator-associated pneumonia. Semin Respir Crit Care Med. 2014;35(4):469\u201381.","journal-title":"Semin Respir Crit Care Med"},{"issue":"11","key":"1281_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11910-015-0594-5","volume":"15","author":"MR Cuero","year":"2015","unstructured":"Cuero MR, Varelas PN. Super-refractory status epilepticus. Curr Neurol Neurosci Rep. 2015;15(11):74.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"12","key":"1281_CR30","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/epi.13584","volume":"57","author":"LM Kortland","year":"2016","unstructured":"Kortland LM, Alfter A, Bahr O, Carl B, Dodel R, Freiman TM, Hubert K, Jahnke K, Knake S, von Podewils F, et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia. 2016;57(12):2056\u201366.","journal-title":"Epilepsia"},{"issue":"3","key":"1281_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12028-008-9168-6","volume":"10","author":"C Cereda","year":"2009","unstructured":"Cereda C, Berger MM, Rossetti AO. Bowel ischemia: a rare complication of thiopental treatment for status epilepticus. Neurocrit Care. 2009;10(3):355\u20138.","journal-title":"Neurocrit Care"},{"key":"1281_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s13054-015-1112-5","volume":"19","author":"A Krajcova","year":"2015","unstructured":"Krajcova A, Waldauf P, Andel M, Duska F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care. 2015;19:398.","journal-title":"Crit Care"},{"issue":"16","key":"1281_CR33","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0000000000003224","volume":"87","author":"V Alvarez","year":"2016","unstructured":"Alvarez V, Lee JW, Westover MB, Drislane FW, Novy J, Faouzi M, Marchi NA, Dworetzky BA, Rossetti AO. Therapeutic coma for status epilepticus: differing practices in a prospective multicenter study. Neurology. 2016;87(16):1650\u20139.","journal-title":"Neurology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1281-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1281-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1281-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T19:09:22Z","timestamp":1586027362000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1281-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1281-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,6]]},"assertion":[{"value":"27 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval is not required for this review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"55"}}